Icosavax Stock Story

ICVX -  USA Stock  

USD 15.53  0.17  1.11%

Today's article will break down Icosavax. We will analyze why it could be a much better year for Icosavax shareholders. Here I will also expose some primary fundamental factors affecting Icosavax's services, and outline how it will impact the outlook for investors this year.
Published over a month ago
View all stories for Icosavax | View All Stories
Is Icosavax about to turn this around?

How does Icosavax utilize its cash?

To perform a cash flow analysis of Icosavax, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Icosavax is receiving and how much cash it distributes out in a given period. The Icosavax cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Icosavax Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Icosavax reported Net Cash Flow from Operations of (12.79 Million) in 2021

Icosavax Gross Profit

Icosavax Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Icosavax previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Icosavax Gross Profit growth over the last 10 years.
Please check Gross Profit in more details.

What did Icosavax file with SEC?

The SEC filings are financial statements or other formal documents of Icosavax that are regularly submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make SEC filings and fintech professionals rely on these filings for information about companies they are evaluating for investment purposes. Please note, most SEC filings are available online through the SEC's EDGAR database.
Please check here for more information.
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Icosavax shareholders may or may not be submitted as SEC does not always require it.
7th of January 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
5th of January 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
12th of August 2021
Unclassified Corporate Event. Unclassified Corporate Event
5th of August 2021
Other Events
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Icosavax shareholders may or may not be submitted as SEC does not always require it.

Acquisition by Shiver John W of 25500 shares of Icosavax subject to Rule 16b-3

Legal trades by Icosavax insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Icosavax insider trading alert for grant of stock option (right to buy) by Shiver John W, the corporate stakeholder, on 5th of January 2022. This event was filed by Icosavax Inc with SEC on 2022-01-05. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Another angle On Icosavax

Roughly 100.0 (percent) of Icosavax outstanding shares are held by regular investors with 0.0 % owned by insiders and only 0.0 pct. by outside corporations.

Ownership Breakdown

Retail Investors
Retail Investors100.0

Our perspective of the current Icosavax rise

Current Risk Adjusted Performance is up to -0.01. Price may slide again. Icosavax is displaying above-average volatility over the selected time horizon. Investors should scrutinize Icosavax independently to ensure intended market timing strategies are aligned with expectations about Icosavax volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Icosavax's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Icosavax's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Icosavax Implied Volatility

Icosavax's implied volatility exposes the market's sentiment of Icosavax stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Icosavax's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Icosavax stock will not fluctuate a lot when Icosavax's options are near their expiration.

While other entities under the biotechnology industry are still a bit expensive, Icosavax may offer a potential longer-term growth to investors. To conclude, as of the 28th of November 2021, we see that Icosavax slowly supersedes the market. The company is undervalued with average chance of financial distress within the next 24 months. However, our overall 90 days advice on the company is Sell.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Icosavax. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com